LOTIS-3 trial: what clinicians have said so far
Safety and Efficacy Study of Loncastuximab Tesirine + Ibrutinib in Diffuse Large B-Cell or Mantle Cell Lymphoma
- NCT03684694 ↗
- Terminated
- ADC Therapeutics S.A.
- Focused size, estimated: 1–150 verified statements once built
We haven't built an HCP commentary report on LOTIS-3 (loncastuximab tesirine plus ibrutinib in advanced diffuse large B-cell or mantle cell lymphoma) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on LOTIS-3 so far
Podcasts, YouTube videos and posts on X and Bluesky we have indexed that name the trial. LinkedIn posts are read for reports and the Enterprise MCP, not yet for this index. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Indexed so far | |
|---|---|
| 2 posts on X, typically up to 9 once built | |
| 1 YouTube video, typically up to 4 once built |
The trial
ClinicalTrials.gov- Official title
- A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of Loncastuximab Tesirine and Ibrutinib in Patients With Advanced Diffuse Large B-Cell Lymphoma or Mantle Cell Lymphoma (LOTIS-3)
- Phase
- Phase 1/Phase 2
- Status
- Terminated
- Conditions
- Diffuse Large B-Cell Lymphoma; Mantle Cell Lymphoma
- Interventions
- Loncastuximab Tesirine; Ibrutinib
- Arms
- Phase 1: Dose-Escalation of ADCT-402 · Experimental
- Phase 2: MTD or RP2D of ADCT-402 in Non-GCB DLBCL · Experimental
- Phase 2: MTD or RP2D of ADCT-402 in GCB DLBCL · Experimental
- Phase 2: MTD or RP2D of ADCT-402 in MCL · Experimental
- Enrollment
- 136
- Primary outcomes
- Phase 1: Number of Participants With Treatment-emergent Adverse Events (TEAEs)
- Phase 1: Number of Participants With Serious TEAEs
- Phase 1: Number of Participants With Dose-Limiting Toxicities (DLTs)
- Phase 1: Number of Participants With Dose Interruptions
- Phase 1: Number of Participants With Dose Reductions
- Phase 2: Complete Response Rate (CRR)
- Sponsor
- ADC Therapeutics S.A.
- Start
- Dec 1, 2018
- Primary completion
- Nov 8, 2022
- Results posted
- Yes
- Registry record
- NCT03684694 · updated Feb 6, 2024